🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ORMP ORMP

Company Profile ↓
$4.32
+121.72% 1Y
Mkt Cap$169.67M
P/E2.88
P/B0.85
52W High$5.00
52W Low$1.92
Book Value$5.09
EPS (TTM)$1.50

Company Overview

ORMP (ORMP) is a publicly traded company listed on with a market capitalization of $169.67M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 32.1%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 13.5% CAGR over the past five years.

Reasonable Valuation

Trades at an undemanding P/E of 2.9.

Recent Developments

  • 5-Year Trend Long-term compounding — revenue CAGR 13.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.48%
1 Year:-

Stock Price Performance

1 Year:+121.72%
6 Months:+26.69%
3 Months:+8.54%
1 Month:+0.47%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 78% of range
$1.92 $5.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)54.82 · Neutral
Price Performance
1M+0.47%
3M+8.54%
6M+26.69%
1Y+121.72%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 32.1%.
  • Compounding revenue at 13.5% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
2.88
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$5.09
Price to Book
0.85
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
13.48%
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-7.12%
ROE
32.07%
ROA
27.74%
Profit Margin
-
Op Margin
-
Gross Margin
0.65%
EPS (Latest Qtr)
$0.91
EPS (TTM)
$1.50

Balance Sheet & Liquidity

Debt/Equity
0.41
Quick Ratio
-
Current Ratio
6.98
Debt
$825.00K
Total Assets
$268.85M
Current Assets
$68.15M
Working Capital
$114.19M

Ownership

Promoter Holding
17.93%
Chg in Prom Hold
0.00%
FII / Inst Holding
32.63%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$2.00M
EBITDA
$75.44M
Free Cash Flow
$-11.08M
Operating Cash Flow
$-9.14M
Shares Outstanding
39.28M
Gross Margin
0.65%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Nov 2014Feb 2015May 2015Nov 2015Feb 2016May 2016Nov 2016Feb 2017May 2017Nov 2017Feb 2018May 2018Nov 2018Feb 2019May 2019Nov 2019Feb 2020May 2020Nov 2020Feb 2021Mar 2021May 2021Jun 2021Sep 2021Nov 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ----125.00K-163.00K610.00K611.00K617.00K611.00K604.00K617.00K674.00K666.00K682.00K674.00K674.00K681.00K674.00K665.00K666.00K681.00K674.00K682.00K674.00K666.00K674.00K682.00K666.00K674.00K-----2.00M0000
Cost of Revenue -----------------------------------1.99M0000
Gross Profit -----------------------------------13.00K0000
Operating Expenses -----------------------------------4.51M2.49M2.43M5.67M3.66M
Operating Income -1.90M-1.67M-1.63M2.45M-1.91M2.11M-2.40M-3.37M-2.15M-2.73M-3.11M-4.53M-4.64M-3.57M-4.08M-2.43M-4.04M-2.27M-5.83M-4.87M-6.60M-6.12M-4.45M-7.49M-8.06M-11.25M-11.42M-8.19M-5.21M-3.79M-2.89M-2.96M-3.13M-3.09M--4.50M-2.49M-2.43M-5.67M-3.66M
EBITDA ------------------------------------4.47M13.16M59.48M9.83M-3.63M
Interest Expense ----------------------------------02.56M000-
Pretax Income ------------------------------------7.06M13.13M59.45M9.80M49.44M
Tax Provision -----------------------------------584.00K-126.00K11.06M-212.00K11.13M
Net Income -1.90M-1.64M-1.58M-2.39M-1.82M2.00M-2.64M-3.18M-1.97M-2.53M-2.92M-4.35M-4.30M3.70M4.07M-2.54M-3.69M-2.28M-5.57M-4.61M-6.06M-5.21M-3.91M--8.10M-10.71M-10.53M-7.06M-3.40M-1.19M-3.22M1.54M9.21M-19.62M--7.64M13.29M48.40M10.01M38.31M
Diluted EPS ----------------------0.120.21-0.270.270.18-0.08-0.03-0.080.040.22-0.48--0.190.311.13-0.91
R&D Expense 1.30M1.14M915.00K-1.90M1.30M-1.71M2.35M3.12M2.27M2.33M2.72M4.19M4.35M3.11M3.86M2.02M3.32M1.93M5.77M3.87M6.17M5.50M3.20M6.09M6.41M5.84M9.18M5.35M4.43M1.82M957.00K1.18M1.44M2.24M-2.21M1.03M1.15M-1.59M

Profit & Loss (Annual)

Figures in USD.

Metric Aug 2008Aug 2009Aug 2010Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------641.00K2.46M2.45M2.70M2.71M2.70M2.70M1.34M02.00M
Cost of Revenue ----------------01.99M
Gross Profit ----------------013.00K
Operating Expenses --------------43.30M17.11M12.78M15.10M
Operating Income ----2.44M-2.88M4.30M-5.91M-7.38M-10.01M-10.77M-13.53M-14.63M-11.76M-24.22M-40.60M-15.77M-12.78M-15.09M
EBITDA ---------------37.61M7.32M-14.87M75.44M
Interest Expense --------------02.04M853.00K0
Pretax Income ---------------37.66M5.09M-15.92M75.32M
Tax Provision --------------100.00K03.18M11.31M
Net Income -2.77M-2.76M-2.98M-1.56M-3.34M4.23M-5.70M-7.23M-10.96M-10.48M-12.73M-14.36M-11.51M-22.99M-36.56M5.53M-19.06M64.05M
Diluted EPS ---------------0.940.14-0.481.50
R&D Expense ---1.16M1.68M-2.27M3.28M4.78M7.71M10.28M11.98M13.52M10.23M20.99M27.64M8.97M6.32M6.38M

Balance Sheet (Annual)

Figures in USD.

Metric Apr 2002Aug 2007Aug 2008Aug 2009Aug 2010Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -----4.33M5.29M8.66M21.80M26.35M42.83M38.71M47.40M34.66M44.63M-177.82M161.64M220.55M155.28M230.86M
Current Assets -----------------157.11M162.58M143.22M133.27M
Cash & Equivalents -----1.51M4.43M2.27M1.76M3.21M3.91M3.97M5.00M3.33M19.30M--40.46M9.05M54.42M45.95M
Inventory ---------------------
Receivables -------------------04.64M
Total Liabilities -----------------10.49M57.66M9.93M31.12M
Current Liabilities -----441.29K644.42K498.00K973.00K1.49M3.62M5.17M4.55M5.31M4.54M-7.37M5.75M53.21M5.68M19.09M
Long Term Debt ------------11.39M9.66M-------
Total Debt -----------------894.00K51.62M372.00K825.00K
Total Equity 53.70K513.13K4.59M2.75M830.27K3.72M3.78M8.13M20.79M24.83M26.19M19.24M31.11M19.39M32.88M-166.45M151.81M163.82M146.26M199.74M
Shares Outstanding -----------------39.56M40.34M39.92M39.28M

Cash Flows (Annual)

Figures in USD.

Metric Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.71M-2.30M-3.40M-4.07M-4.95M4.66M-5.83M-14.66M-12.94M-12.44M--27.92M-10.29M-8.41M-9.14M
Investing Cash Flow -1.70M1.77M-4.57M-13.09M-3.31M-16.01M4.30M-7.00M11.26M4.63M-30.21M-73.04M105.82M5.44M
Financing Cash Flow 3.69M3.49M5.82M16.64M9.72M12.04M1.59M22.65M-23.79M-10.78M51.98M-52.04M-4.74M
Capital Expenditure -2.18K-2.00K-6.00K-14.00K-1.00K-9.00K-7.00K-5.00K-15.00K-82.00K--496.00K-254.00K-18.00K-1.93M
Free Cash Flow -1.71M-2.30M-3.40M-4.08M-4.95M4.65M-5.84M-14.66M-12.96M-12.52M--28.41M-10.55M-8.43M-11.08M
Net Change in Cash -----------13.07M-31.36M45.37M-8.44M
Share Buybacks -------------2.48M4.74M

Ratios (Annual)

Figures in %.

Metric Aug 2008Aug 2009Aug 2010Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------0.7%
Operating Margin % ---------1,561.6%-438.6%-552.3%-541.3%-433.8%-896.2%-1,502.0%-1,176.8%--754.4%
Net Margin % ---------1,710.5%-426.7%-519.7%-531.1%-424.8%-850.5%-1,352.6%412.3%-3,202.5%
ROE % -60.3%-100.5%-358.6%-41.9%-88.5%52.0%-27.4%-29.1%-41.9%-54.5%-40.9%-74.0%-35.0%--24.1%3.4%-13.0%32.1%
ROCE % ----62.7%-62.0%52.7%-28.4%-29.7%-25.5%-32.1%-31.6%-49.8%-29.3%--26.0%-9.4%-8.5%-7.1%

Shareholding Pattern

Insiders
17.93%
Institutions
32.63%
Public Float
39.77%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ORMP

Google News Mon, 03 Aug 2026

ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQTHR1Z3lKVmgxbWQtd2FVU3FfOEVVNzlGb2Z2R1NoRDhjR0FWdjFZNEg4Ql80MGFNZjFQUFphMVRHaUNEZVJvZkg2MXJ1Qm9NbjNZVUFmLTlobVZxaTcxTm9aSDllVUJualA2VFhJajRuMFZpelYtNDBIYlFzYzUwcUVrdE80MlVDSm5zY3…

Google News Wed, 17 Jun 2026

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PR Newswire

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNjZlb2hsYnJCTE03WUdqR1VwelhzWGtOb29vcUFIUmlfNzRWUUdBMGlIdnRtdEZBM3dkb20zaTg1MEhZc29EYVNmVE1mc2xoODkwS3pRVjh4X3FqLWFLYjkwMEFtTzNEWEcwNmRqUkVJWkl0bkxJZkF6MC11LVZiNDdpeEE0MWhWUnlCVH…

Google News Fri, 22 May 2026

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxONmpPQmZvbGJpM1R4MTR6WHhUVVV0eHFLZjhkaW5oamlpWS1kZWZ1OFVjcTdiaW5iS0EtbTdhMHg2OU9jSlE1UUNOZXVuWFpmSWlRNW1kUEhFdlA0c1FZMDZXNy1Ec1J3bDFoLURQV3lUOHNjVng0RjNQZ3RsOURnRlprRGd4bTRhdXlZSH…

Google News hu, 25 Jun 2026

Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP) - TradingView

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOYXI4ZHlvZGhOeGo4MXlGOHgySzVmWUkxSFVTSXNITlAzbDdGdzE4R3VERGdydWdMTGpoLWRYRWlHY2xiRHVmcnJmRW16bWFWSFF5bWlHaUIyRUlSVE53b3RyNmVlcjVaRTlzaXJpdURhUGdCNXUtOHg3aXJHOEhCY3ZLRHBxZw?oc=5" t…

Google News Fri, 31 Jul 2026

ORMP|Oramed Pharmaceuticals Inc|Price:4.250|Chg%:+0.180 - TradingKey

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5FcGtzREZjSVJnTlppQkNfUTU3MUxCbTcxaHl4OHZNMHFkcmFCbFk3d1BiN2VSUmFHQmZfVC1QbXZkUUdsc2hoMjVoVmV5Y1hYMF90WVlXSUJ5ZGxOVUo3OEt1NEpvMGQyZFZWMG1R?oc=5" target="_blank">ORMP|Oramed Pharmac…

Google News Fri, 21 Nov 2025

Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPU0pmdm5tZXlyN1hHRWRDelc3SDBvWWRnSnZiZzNLeHdBNExiUElpdm1PV1E2UldnX2h6a0EwR2NFY0JpYjBaS0hFejJNQThCNHlsQTFfa05acmZOSlJXNWpKbktDbHJudThkNnM4U1lzaHozUGZpc2h4bnJYZ29Va0ZWeXZmcWtRV2d3Yl…

ORMP — Frequently Asked Questions

What is the current share price of ORMP?

As of 2026-08-05 17:25 PDT, ORMP trades at $4.32 on NASDAQ/NYSE. Its 52-week range is $1.92 to $5.00.

What is the market capitalisation of ORMP?

ORMP has a market capitalisation of $169.67M on NASDAQ/NYSE.

What is the P/E ratio of ORMP?

ORMP trades at a trailing price-to-earnings (P/E) ratio of 2.88. Its price-to-book (P/B) ratio is 0.85.

What is the return on equity (ROE) of ORMP?

ORMP has a return on equity (ROE) of 32.07%. Its return on capital employed (ROCE) is -7.12%.

Is ORMP a good stock to buy?

This page provides a data-driven analysis of ORMP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space